The financials
Adaptive Biotechnologies Corporation by the numbers
Adaptive Biotechnologies Corporation (ADPT) reported revenue of $72M in Q2 2026 (quarter ended June 30, 2026), up 22% from the same quarter a year earlier. That came with a gross margin of 72% and net loss of $40M. For the full year FY2025, revenue was $277M (+55% year on year) and net income −$59M. Its largest product in 2026-Q1 was Service at $58M, 82% of the disclosed total, just ahead of Regulatory Milestone at 13%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $72M | $59M | +22% |
| Gross profit | $51M | $41M | +26% |
| Operating income | −$16M | −$25M | n/a |
| Net income | −$40M | −$26M | n/a |
| Diluted EPS | −$0.25 | −$0.17 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Service | $58M | 82% |
| Regulatory Milestone | $9.0M | 13% |
| Service And Licensing | $3.8M | 5.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $70.9M (-24%)
Regulatory Milestone grew +100% year on yearCollaboration -100% year on year
Segment Latestquarter on quarteryear on year
- Service$58.1M$58.1MQoQ +16%year on year +48%+16%+48%
- Regulatory Milestone$9.0M$9.0MQoQ +38%year on year +100%+38%+100%
- Service And Licensing$3.8M$3.8MQoQ -year on year ---
- Collaboration$0.00$0.00QoQ -100%year on year -100%-100%-100%
- Immune Medicine Service--QoQ -year on year ---
Diagnostics & Research
Ranks #6 of 29 by Smart Score